• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与强烈激活的刺猬信号通路相关的表达缺失预示着切除的胰腺癌预后不良。

The Loss of Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer.

作者信息

Xu Jin-Zhi, Wang Wen-Quan, Zhang Wu-Hu, Xu Hua-Xiang, Gao He-Li, Zhang Shi-Rong, Wu Chun-Tao, Li Shuo, Li Hao, Xu Jin, Yu Xian-Jun, Liu Liang

机构信息

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

J Cancer. 2019 Jul 10;10(17):4123-4131. doi: 10.7150/jca.30883. eCollection 2019.

DOI:10.7150/jca.30883
PMID:31417657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6692626/
Abstract

: Pancreatic ductal adenocarcinoma (PDAC) progression is mediated by mutations in driver genes and a complex stroma that is mainly dependent on the Sonic hedgehog (Shh) signaling pathway. However, the association between driver genes and Shh-pathway proteins and their potential prognostic significance remain unclear. : We analyzed protein expressions of the , and driver genes and the Shh-pathway molecules, including Shh, glioma-associated oncogene (Gli) 1, Gli2, and smoothened (SMO) by immunohistochemistry using tissue microarrays in 237 patients with resectable PDAC and statistically determined their prognostic significance. : mutation was associated with shorter survival outcomes [overall survival (OS): Hazard ratio (HR) 1.887, < 0.001]; recurrence-free survival (RFS): HR 1.886, < 0.001) and abnormal p53 immunolabeling was associated with poor OS (HR 1.436, = 0.011) in patients with PDAC. The mutational status of p16 had no effect on patient survival. High levels of SMO and Gli1 expression were associated with poor survival outcomes in both univariate and multivariate analyses. Pearson's χ test showed a medium correlation between the mutation and Shh (R = 0.343) and Gli1 (R = 0.505) expression levels ( < 0.001). Patients with the mutation and high levels of Shh and Gli1 expression showed the poorest survival outcomes (RFS: HR 2.976; OS: HR 3.598; < 0.001 for both) compared with other patients in the study. : Loss of associated with a strongly activated Shh pathway resulted in poor survival outcomes in patients with resected PDAC.

摘要

胰腺导管腺癌(PDAC)的进展由驱动基因突变和主要依赖于音猬因子(Shh)信号通路的复杂基质介导。然而,驱动基因与Shh通路蛋白之间的关联及其潜在的预后意义仍不清楚。我们通过免疫组织化学方法,利用组织芯片分析了237例可切除PDAC患者中 、 和 驱动基因以及Shh通路分子(包括Shh、胶质瘤相关癌基因(Gli)1、Gli2和平滑肌样蛋白(SMO))的蛋白表达,并通过统计学方法确定了它们的预后意义。 在PDAC患者中, 突变与较短的生存结局相关[总生存期(OS):风险比(HR)1.887, < 0.001];无复发生存期(RFS):HR 1.886, < 0.001),且p53免疫标记异常与较差的OS相关(HR 1.436, = 0.011)。p16的突变状态对患者生存无影响。在单因素和多因素分析中,高水平的SMO和Gli1表达均与较差的生存结局相关。Pearson卡方检验显示, 突变与Shh(R = 0.343)和Gli1(R = 0.505)表达水平之间存在中等程度的相关性( < 0.001)。与研究中的其他患者相比,具有 突变且Shh和Gli1表达水平高的患者生存结局最差(RFS:HR 2.976;OS:HR 3.598;两者均 < 0.001)。与Shh通路强烈激活相关的 缺失导致切除的PDAC患者生存结局较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/25fc22d3cf47/jcav10p4123g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/71bface321e7/jcav10p4123g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/b1f625f3ad72/jcav10p4123g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/25fc22d3cf47/jcav10p4123g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/71bface321e7/jcav10p4123g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/b1f625f3ad72/jcav10p4123g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7271/6692626/25fc22d3cf47/jcav10p4123g003.jpg

相似文献

1
The Loss of Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer.与强烈激活的刺猬信号通路相关的表达缺失预示着切除的胰腺癌预后不良。
J Cancer. 2019 Jul 10;10(17):4123-4131. doi: 10.7150/jca.30883. eCollection 2019.
2
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.免疫组化检测到 3 个主要基因(CDKN2A/p16、TP53 和 SMAD4/DPC4)的表达水平强烈预测了可切除胰腺癌患者的生存情况。
Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.
3
Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.KRAS 和 SMAD4 基因突变联合在福尔马林固定石蜡包埋组织中作为胰腺癌的生物标志物。
Cancer Sci. 2020 Jun;111(6):2174-2182. doi: 10.1111/cas.14425. Epub 2020 May 30.
4
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的浸润免疫细胞和基因突变。
Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.
5
P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy.超声内镜引导下细针穿刺活检中 P53 免疫组化染色可预测新辅助治疗后可切除或交界可切除胰腺癌的低切除率和早期复发。
J Hepatobiliary Pancreat Sci. 2023 Jun;30(6):802-814. doi: 10.1002/jhbp.1286. Epub 2022 Dec 20.
6
Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.根据 KRAS 突变以及 CDKN2A、p53 和 SMAD4 表达情况评估胰腺癌患者的术后死亡率和复发模式。
J Pathol Clin Res. 2023 Sep;9(5):339-353. doi: 10.1002/cjp2.323. Epub 2023 Jun 8.
7
Association of expression of the hedgehog signal with Merkel cell polyomavirus infection and prognosis of Merkel cell carcinoma.刺猬信号通路的表达与默克尔细胞多瘤病毒感染及默克尔细胞癌预后的相关性
Hum Pathol. 2017 Nov;69:8-14. doi: 10.1016/j.humpath.2017.05.011. Epub 2017 Jun 28.
8
High expression of Sonic hedgehog signaling proteins is related to the favorable outcome, EGFR mutation, and lepidic predominant subtype in primary lung adenocarcinoma.原发性肺腺癌中 Sonic hedgehog 信号蛋白的高表达与良好的预后、EGFR 突变和贴壁为主型相关。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S570-6. doi: 10.1245/s10434-013-3022-6. Epub 2013 May 26.
9
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.DPC4/Smad4在胰腺导管腺癌中的表达与预后
J Clin Oncol. 2002 Dec 1;20(23):4531-42. doi: 10.1200/JCO.2002.12.063.
10
Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. hedgehog 信号通路分子和 ALDH1A1 在早期非小细胞肺癌中的表达。
Lung Cancer. 2012 May;76(2):191-6. doi: 10.1016/j.lungcan.2011.10.015. Epub 2011 Nov 23.

引用本文的文献

1
Drivers of Pancreatic Cancer: Beyond the Big 4.胰腺癌的驱动因素:超越四大因素
Cancers (Basel). 2025 Jul 15;17(14):2354. doi: 10.3390/cancers17142354.
2
SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy.SMAD4 限制 PARP1 依赖性 DNA 修复以使胰腺癌细胞对放射治疗敏感。
Cell Death Dis. 2024 Nov 11;15(11):818. doi: 10.1038/s41419-024-07210-7.
3
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.TP53、CDKN2A、SMAD4和KRAS在胰腺癌中的意义

本文引用的文献

1
Reflections on depletion of tumor stroma in pancreatic cancer.对胰腺癌肿瘤基质耗竭的思考。
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):267-272. doi: 10.1016/j.bbcan.2019.01.007. Epub 2019 Feb 6.
2
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.进化途径和 KRAS 剂量决定胰腺癌细胞表型。
Nature. 2018 Feb 1;554(7690):62-68. doi: 10.1038/nature25459. Epub 2018 Jan 24.
3
Cancer statistics, 2018.癌症统计数据,2018 年。
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
4
Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry.显微镜检查确诊对胰腺癌患者治疗管理的影响:来自意大利某地区肿瘤登记处的经验教训。
Cancers (Basel). 2022 Oct 31;14(21):5372. doi: 10.3390/cancers14215372.
5
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.一种针对 EGFR/HER2 的偶联物通过不同的 SMAD4 介导机制使吉西他滨敏感和耐药的胰腺癌敏感化。
Nat Commun. 2022 Sep 20;13(1):5506. doi: 10.1038/s41467-022-33037-x.
6
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer.胰腺癌经典及新型生物标志物的临床应用
Cancers (Basel). 2022 Apr 7;14(8):1866. doi: 10.3390/cancers14081866.
7
Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature.一名胰腺癌伴肺转移患者的长期生存:病例报告及文献综述
World J Clin Cases. 2021 Oct 26;9(30):9134-9143. doi: 10.12998/wjcc.v9.i30.9134.
8
Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.TGF-β 在胰腺导管腺癌进展和 PD-L1 表达中的作用。
Cell Oncol (Dordr). 2021 Jun;44(3):673-687. doi: 10.1007/s13402-021-00594-0. Epub 2021 Mar 10.
9
Identification of Critical Pathways and Potential Key Genes in Poorly Differentiated Pancreatic Adenocarcinoma.低分化胰腺腺癌关键通路及潜在关键基因的鉴定
Onco Targets Ther. 2021 Jan 27;14:711-723. doi: 10.2147/OTT.S279287. eCollection 2021.
10
Malignant epithelial/exocrine tumors of the pancreas.胰腺的恶性上皮/外分泌肿瘤。
Pathologica. 2020 Sep;112(3):210-226. doi: 10.32074/1591-951X-167.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
4
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.《胰腺导管腺癌临床实践指南(2017 年第 2 版)》,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.
5
Quid pro Quo: A Tumor is Not Alone.以物易物:肿瘤并非孤立存在。
Trends Mol Med. 2017 May;23(5):375-376. doi: 10.1016/j.molmed.2017.03.007. Epub 2017 Apr 10.
6
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.使用靶向深度测序检测评估KRAS、CDKN2A、TP53和SMAD4基因突变数量作为胰腺癌预后生物标志物的效用
Pancreas. 2017 Mar;46(3):335-340. doi: 10.1097/MPA.0000000000000760.
7
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance.转化生长因子-β/ Smad4信号通路在胰腺癌发生中的作用及其临床意义
J Clin Med. 2017 Jan 5;6(1):5. doi: 10.3390/jcm6010005.
8
CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.CA19-9低表达且Lewis阳性的胰腺癌:一种独特的亚型。
Cancer Lett. 2017 Jan 28;385:46-50. doi: 10.1016/j.canlet.2016.10.046. Epub 2016 Nov 10.
9
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.基于基因组重排模式的胰腺癌进化新模型。
Nature. 2016 Oct 20;538(7625):378-382. doi: 10.1038/nature19823. Epub 2016 Oct 12.
10
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的浸润免疫细胞和基因突变。
Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.